Phospho-EphA2 antibody | knockout validation | Cell Applications CY1108
DOI
//dx.doi.org/10.13070/ko.en.7.2112
Date
2017-01-23

This is a knockout-validated antibody summary, based on the publication "EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit polyclonal

Company: Cell Applications

Antibody: Phospho-EphA2 (Ser897)

Catalog number: CY1108

Summary: Rabbit polyclonal antibody raised against a synthetic phospho-peptide corresponding to residues surrounding Ser897 of human EphA2. Supplier recommended for WB, IP, ICC, IHC and FACS. Reacts with human, mouse and rat phospho-EphA2 (Ser897).

Validation Method

Western blot

Sample

Lysates of lung tumor tissue from wild-type and EphA2 knockout mice.

Blocking agent

TBS-T containing 5% milk powder.

Primary incubation

Anti-phospho-EphA2 antibody diluted 1:1000.

Secondary incubation

HRP-conjugated anti-rabbit IgG (Promega).

Detection

Clarity Western ECL reagent (BioRad).

Figure

Please see Figure S4 in [1].

References
  1. Amato K, Wang S, Tan L, Hastings A, Song W, Lovly C, et al. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res. 2016;76:305-18 pubmed publisher